A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in δF508-Homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 2, 1998, Pages 484-490

  Rubenstein, Ronald C ^a,b   Zeitlin, Pamela L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; AMILORIDE; BUTYRIC ACID DERIVATIVE; CHLORIDE ION; GENISTEIN; ISOPRENALINE; MILRINONE; NEW DRUG; PLACEBO; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL MEMBRANE TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; EPITHELIUM CELL; FEMALE; HUMAN; LUNG DISEASE; MALE; NAUSEA; NOSE MUCOSA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031889082     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.2.9706088     Document Type: Article

References (31)

1. Cheng, S. H., R. J. Gregory, J. Marshall, S. Paul, D. W. Souza, G. A. White, C. R. O'Riordan, and A. E. Smith. 1990. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63:827-834.
2. Jensen, T. J., M. A. Loo, S. Pind, D. B. Williams, A. L. Goldberg, and J. R. Riordan. 1995. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83:129-135.
3. Ward, C. L., S. Omura, and R. R. Kopito. 1995. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121-127.
4. Li, C., M. Ramjeesingh, E. Reyes, T. Jensen, X. Chang, J. M. Rommens, and C. E. Bear. 1993. The cystic fibrosis mutation delta F508 does not influence the chloride channel activity of CFTR. Nat. Genet. 3:311-316.
5. Dalemans, W., P. Barbry, G. Champigny, S. Jallat, K. Dott, D. Dreyer, R. G. Crystal, A. Pavirani, J.-P. Lecocq, and M. Lazdunski. 1991. Altered chloride channel kinetics associated with the deltaF508 cystic fibrosis mutation. Nature 354:526-528.
6. Denning, G. M., M. A. Anderson, J. F. Amara, J. Marshall, A. E. Smith, and M. J. Welsh. 1992. Processing of mutant cystic fibrosis transmembrane regulator is temperature-sensitive. Nature 358:761-764.
7. Brown, C. R., L. Q. Hong-Brown, J. Biwersi, A. S. Verkman, and W. J. Welch. 1996. Chemical chaperons correct the mutant phenotype of the deltaF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress & Chaperones 1:117-125.
8. Sato, S., C. L. Ward, M. E. Krouse, J. J. Wine, and R. R. Kopito. 1996. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271:635-638.
9. Sher, G. D., G. D. Ginder, J. Little, S. Yang, G. J. Dover, and N. F. Olivieri. 1995. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N. Engl. J. Med. 332:1606-1610.
10. Perrine, S. P., G. D. Ginder, D. V. Faller, G. J. Dover, T. Ikuta, H. E. Witkowski, S.-P. Cai, E. P. Vichinsky, and N. F. Oliveri. 1993. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N. Engl. J. Med. 328:81-86.
11. Cheng, S. H., S. L. Fang, J. Zabner, J. Marshall, S. Piraino, S. C. Schiavi, D. M. Jefferson, M. J. Welsh, and A. E. Smith. 1995. Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by over-expression. Am. J. Physiol. 268:L615-L624.
12. Perrine, S. P., N. F. Olivieri, D. V. Faller, E. P. Vichinsky, G. J. Dover, and G. D. Ginder. 1994. Butyrate derivatives: new agents for stimulating fetal globin production in the beta-globin disorders. Am. J. Pediatr. Hematol. Oncol 16:67-71.
13. Collins, A. F., H. A. Pearson, P. Giardina, K. T. McDonagh, S. W. Brusilow, and G. J. Dover. 1995. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85:43-49.
14. Carducci, M. A., J. B. Nelson, K. M. Chan-Tack, S. R. Ayyagari, W. S. Sweatt, P. A. Campbell, W. G. Nelson, and J. W. Simons. 1996. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. 2:379-387.
15. Carducci, M., M. Bowling, M. Eisenberger, V. Sinibaldi, J. Simons, T. Chen, D. Noe, L. Grochow, and R. Donehower. 1996. Phenylbutyrate (PB) for refractory solid tumors: a phase I clinical and pharmacological evaluation (abstract). Proc. Annu. Meet. Am. Assoc. Cancer Res. 37:A1152.
16. Rubenstein, R. C., and P. L. Zeitlin. 1997. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest. 100:2457-2465.
17. National Committee for Clinical Laboratory Standards. 1994. Sweat testing: sample collection and quantitative analysis - approved guideline. Wayne, PA.
18. Knowles, M. R., A. M. Paradiso, and R. C. Boucher. 1995. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum. Gene Ther. 6:445-455.
19. Brusilow, S. W. 1991. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr. Res. 29:147-150.
20. Zabner, J., B. W. Ramsey, D. P. Meeker, M. L. Aitken, R. P. Balfour, R. L. Gibson, J. Launspach, R. A. Moscicki, S. M. Richards, T. A. Standaert, J. Williams-Warren, S. C. Wadsworth, A. E. Smith, and M. J. Welsh. 1996. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. 97:1504-1511.
21. Zabner, J., S. H. Cheng, D. Meeker, J. Launspach, R. Balfour, M. A. Perricone, J. E. Morris, J. Marshall, A. Fasbender, A. E. Smith, and M. J. Welsh. 1997. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J. Clin. Invest. 100:1529-1537.
22. Quinton, P. M. 1983. Chloride impermeability in cystic fibrosis. Nature 301:421-422.
23. Ucyclyd Pharma, Inc. 1996. Buphenyl package insert. Hunt Valley, MD.
24. Pasyk, E. A. and J. K. Foskett. 1995. Mutant deltaF508 cystic fibrosis transmembrane conductance regulator Cl-channel is functional when retained in endoplasmic reticulum of mammalian cells. J. Biol. Chem. 270:12347-12350.
25. Sheppard, D. N., D. R. Rich, L. S. Ostergaard, R. J. Gregory, A. E. Smith, and M. J. Welsh. 1993. Mutations in CFTR associated with mild-disease-form Cl channels with altered pore properties. Nature 362:160-164.
26. Walker, L. C., C. J. Venglarik, G. Aubin, M. R. Weatherly, N. A. McCarty, B. Lesnick, F. Ruiz, J. P. Clancy, and E. J. Sorscher. 1997. Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR. Am. J. Respir. Crit. Care Med. 155:1684-1689.
27. Hwang, T.-C. 1996. Genistein rescues channel function of the deltaF508 CFTR. Pediatr. Pulmonol. 13(Suppl.):257.
28. Guay-Broder, C., K. A. Jacobson, S. Barnoy, Z. I. Cabantchik, W. B. Guggino, P. L. Zeitlin, R. J. Turner, L. Vergara, O. Eidelman, and H. B. Pollard. 1995. Al receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry 34:9079-9087.
29. Kelley, T. J., L. al-Nakkash, C. U. Cotton, and M. L. Drumm. 1996. Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J. Clin. Invest. 98: 513-520.
30. Kelly, T. J., K. Thomas, L. J. H. Hilgram, and M. L. Drumm. 1997. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium. Proc. Natl. Acad. Sci. U.S.A. 94:2604-2608.
31. McCance, R. A. 1938. The effect of salt deficiency in man on the volume of the extracellular fluids, and on the composition of sweat, saliva, gastric juice and cerebrospinal fluid. J. Physiol. 92:208-218.